Provigil Non-Responder Profile: Who Does Modafinil Not Work For?

Is there a published non-responder profile for modafinil?

The trials cited here report group results, not a profile of who fails. The clearest response figure comes from shift work disorder, where 74% of patients on modafinil improved clinically versus 36% on placebo [3]. The narcolepsy trials, in 283 and 271 patients, reported average change on sleepiness scales rather than the share of individuals who crossed a response line [4][5].

What the narcolepsy and shift-work trials measured

The first US multicenter narcolepsy trial gave 283 patients modafinil 200 mg, 400 mg or placebo for 9 weeks. Modafinil significantly reduced sleepiness on the Epworth Sleepiness Scale, the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test, and improved clinician-rated change; adverse experiences were few and mostly mild to moderate [4]. A second 9-week trial in 271 patients found significant improvement on the same objective and subjective measures [5]. Both report group averages.

The shift-work trial randomized 209 patients to modafinil 200 mg or placebo before each shift for three months. Nighttime sleep latency improved by 1.7 minutes versus 0.3 minutes on placebo, 74% versus 36% improved clinically, and fewer patients on modafinil reported accidents or near-accidents while commuting home (29% versus 54%). Even with this improvement, patients taking modafinil remained excessively sleepy at night [3].

In 254 night-shift workers, armodafinil 150 mg before each shift raised mean sleep latency from 2.3 to 5.3 minutes, against 2.4 to 2.8 minutes on placebo, and 79% versus 59% improved clinically [7].

Uses outside the approved indications

Modafinil is not FDA-approved for depression, fatigue from other conditions, jet lag or cognitive enhancement; those are off-label uses [6]. Results differ by condition: modafinil did not separate from placebo for MS fatigue [1], while an analysis of modafinil or armodafinil added to depression treatment found improvement [8].

Multiple sclerosis fatigue. In a randomized, placebo-controlled crossover trial, 141 people with MS fatigue were enrolled and 136 entered the primary analysis. Modafinil, up to 100 mg twice daily, did not separate from placebo on the Modified Fatigue Impact Scale taken at the highest tolerated dose: placebo 40.6, modafinil 39.0, overall p=0.20 [1].

Depression. A meta-analysis of 6 randomized trials and 910 patients found that adding modafinil or armodafinil to standard treatment improved depression scores (effect -0.35, 95% CI -0.61 to -0.10) and remission odds (odds ratio 1.61, 95% CI 1.04 to 2.49), with adverse events not different from placebo. The included trials were short and modest in size [8].

Cognitive enhancement in healthy adults. Across 14 studies, modafinil produced a small overall effect on cognition (standardized mean difference 0.12, p=.01), with a larger effect on memory updating (0.28, p=.03). The authors concluded that the user perception that these drugs are effective cognitive enhancers is not supported by the evidence so far [2].

Obstructive sleep apnea

In OSA, the label is explicit that modafinil treats the sleepiness and not the underlying airway obstruction, and that a maximal effort with CPAP should be made before and during treatment [6]. A systematic review and meta-analysis of 8 randomized trials in CPAP-treated patients found modafinil and armodafinil improved excessive daytime sleepiness, attention and alertness, and clinician-rated condition, but not quality of life, memory, executive function or language. There were no severe adverse effects but significantly more dropout than with placebo [9].

The label also says that wakefulness may not return to normal on modafinil, and that patients should be frequently reassessed for sleepiness and, if appropriate, advised to avoid driving or other potentially dangerous activity [6].

Side effects and discontinuation

Some patients discontinued modafinil because of adverse reactions. In pooled placebo-controlled trials of 934 patients on modafinil and 567 on placebo, 8% of modafinil patients discontinued for an adverse reaction versus 3% on placebo. Headache occurred in 34% versus 23%, nausea 11% versus 3%, nervousness 7% versus 3%, anxiety 5% versus 1%, and insomnia 5% versus 1% [6]. Headache and anxiety were the dose-related reactions [6].

Psychiatric history

In adult trials, anxiety and nervousness each led to discontinuation in 1% of patients, with insomnia, confusion, agitation and depression below 1% [6]. Postmarketing reports include mania, delusions, hallucinations, suicidal ideation and aggression, some requiring hospitalization; many, but not all, of those patients had a prior psychiatric history. The label advises caution in people with a history of psychosis, depression or mania and consideration of discontinuation if psychiatric symptoms develop [6]. A prior psychiatric history is not an established non-response profile.

Dosing and timing in the label

For narcolepsy or OSA, the label gives 200 mg once a day as a single morning dose. For shift work disorder, it gives 200 mg about 1 hour before the start of the shift [6]. In severe hepatic impairment the dose is halved, and lower doses with close monitoring are suggested for geriatric patients [6]. Doses up to 400 mg a day are well tolerated, but there is no consistent evidence that 400 mg adds benefit over 200 mg [6].

Food does not change overall absorption but can delay the peak by about 1 hour. The drug peaks 2 to 4 hours after a dose with an effective half-life of about 15 hours after multiple doses, reaching steady state in 2 to 4 days [6].

Does modafinil stop working after a few weeks?

The label notes that trough levels fall after several weeks of treatment, suggesting auto-induction of metabolism, and judges this of minimal clinical significance [6]. In the first narcolepsy trial, efficacy was maintained through up to 40 weeks of open-label treatment, which the investigators took as suggesting that tolerance will not develop with long-term use [4]. In the second narcolepsy trial, after 9 weeks of treatment, patients entered a 2-week discontinuation phase; sleepiness returned to baseline in those who had received modafinil, without amphetamine-type withdrawal symptoms [5].

Metabolism and the armodafinil switch

Modafinil is about 90% eliminated by liver metabolism, principally amide hydrolysis with lesser CYP-mediated oxidative pathways; less than 10% is excreted unchanged, and pharmacokinetics are dose-independent between 200 and 600 mg a day [6][10]. A pharmacokinetic review notes that compounds which induce or inhibit CYP activity are unlikely to have major effects on modafinil's pharmacokinetics [10]. The Provigil label's dosage section lists adjustments for severe hepatic impairment and for geriatric patients [6].

Armodafinil is the R-enantiomer of modafinil. According to the Nuvigil label, because the S-enantiomer clears faster (half-life about 4 hours), 200 mg of armodafinil gives higher late-day levels than 200 mg of modafinil: at steady state, peak concentration about 37% higher and total exposure about 70% higher.

What the AASM guideline recommends for narcolepsy

The American Academy of Sleep Medicine 2021 clinical practice guideline gives strong recommendations for adults with narcolepsy for modafinil, pitolisant, sodium oxybate and solriamfetol [11]. The Provigil label states that the mechanism by which modafinil promotes wakefulness is unknown [6].